Low Dose Lithium‐Carbimazole in the Treatment of Thyrotoxicosis

Summary: Low dose lithium‐carbimazole in the treatment of thyrotoxicosis. J. M. Hedley, J. G. Turner, B. E. W. Brownlie and W. A. Sadler, Aust. N.Z. J. Med., 1978, 8, pp. 628–630. Fifteen patients with thyrotoxicosis were treated with low dose sustained release lithium carbonate 400 mg, combined with carbimazoie 40 mg daily, and the therapeutic response was followed over a two week period. This response was compared with that obtained in a similar group of patient treated with carbimazoie alone. Li‐carbimazole treatment brought about a fall in the mean total serum T4 of 57 4% compared with a drop of 328% in patients treated with carbimazoie alone. The mean serum T3 fell by 69‐4% in the Li‐carbimazoie group compared with 47‐3% in the group treated with carbimazoie only. No lithium adverse effects were encountered.